HealthyMICROPEPSNCT07276464
Characterization of the Gut Microbiota Signature According to Physical Fitness and Its Implications for Intestinal Health.
An observational study of Healthy, run by University of Rennes 2 at 1 site in France.
Trial summary
The gut microbiota comprises all microorganisms inhabiting the digestive tract, evolving throughout life under the influence of various intrinsic and extrinsic factors. Under healthy conditions, the microbiota remains stable, resilient, and maintains a symbiotic relationship with its host. Read more about this study
- Who is it for?
- Ages 18 to 30 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Healthy
- What is being tested?
- Maximal incremental exercise test, Submaximal exercise test and Fecal sampling
- How many people
- 30 participants
- Where
- 1 siteFrance
- Study dates
- 17 Nov 2025to 18 Jun 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 30 years
- Men only
- Healthy volunteers accepted
- Adult
Study population: Populations located in a continuum from inactive people to top-level athletes with high and very high exercise capacity.
Who may be able to join
- Male participant
- Aged between 18 and 30 years (inclusive)
- Body Mass Index (BMI) between 18 and 25 kg/m² (inclusive)
- No history of gastrointestinal disease, including inflammatory bowel disease
- Be a non-smoker.
- Have a regular bowel transit (1-2 bowel movements per day or every other day) without recurrent episodes of diarrhea or constipation
Show all 11Show fewer
- Having provided free, informed, and written consent to participate in the study
- Training status :
- Low to moderate active subjects : Perform 2 to 4 hours per week of moderate to vigorous physical activity (VO₂max between 40 and 50 mL·min-¹·kg-¹).
- Trained subjects : Perform 5 to 7 hours per week of regular endurance training for at least one year (VO₂max between 50 and 65 mL·min-¹·kg-¹).
- Highly trained subjects : Perform at least 10 hours per week of structured endurance training, with daily or twice-daily sessions (VO₂max greater than 65 mL·min-¹·kg-¹).
Who cannot join
- History of cardiovascular disease.
- Presence of a metabolic disorder (e.g., diabetes).
- Use of antibiotics, antifungal, or antiparasitic agents within the past 3 months, or planned use during participation in the study.
- Use of prebiotic and/or probiotic supplements within the 7 days preceding the study, providing ≥10⁸ CFU or organisms per day.
- Current use of medication for chronic pain management, including paracetamol, vasodilators, homeopathic treatments, or aspirin at doses >500 mg/day.
- Simultaneous participation in another clinical study involving human subjects, or recent participation in a previous study for which the exclusion period has not yet expired.
Trial locations and contacts
1 site in 1 country.
France1 site
University Rennes 2 - Laboratory "Movement, Sport and health Sciences"
Bruz, Britanny, 35170
About this study
Official title: Characterization of the Gut Microbiota Metagenomic Signature According to Physical Fitness and Its Implications for Intestinal Health.
The gut microbiota comprises all microorganisms inhabiting the digestive tract, evolving throughout life under the influence of various intrinsic and extrinsic factors. Under healthy conditions, the microbiota remains stable, resilient, and maintains a symbiotic relationship with its host. Conversely, dysbiosis refers to an alteration in microbial composition and function, which has been linked to diseases such as inflammatory bowel disease (IBD). IBD, including Crohn's disease and ulcerative colitis, is associated with a disrupted microbiota compared to healthy individuals, leading to impaired intestinal barrier integrity and activation of local inflammatory pathways.
Increasing evidence also suggests that the gut microbiota of athletes differs from that of physically inactive individuals, showing greater microbial diversity and higher concentrations of short-chain fatty acids (SCFAs). In this context, the present clinical study aims to characterize the bacterial metagenome of the gut microbiota across a continuum ranging from inactive individuals to elite athletes with high or very high energy demands. The ultimate goal of this project is to determine whether specific gut microbiota composition and functional profiles are associated with different levels of exercise capacity, and to create a fecal microbiota biobank for future research on intestinal health.
Read the detailed description
The gut microbiota includes all microorganisms-bacteria, viruses, and fungi-that inhabit the digestive tract. Colonization begins at birth and evolves throughout life under the influence of numerous factors such as diet, antibiotic use, sleep, stress, physical activity, exposure to environmental agents, as well as age, sex, and ethnic or migratory background.
This microbial ecosystem performs several essential functions for its host, including digestion and nutrient absorption, immune regulation, and protection against pathogens. Through the fermentation of complex carbohydrates, particularly dietary fibers indigestible by human enzymes, certain bacteria produce short-chain fatty acids (SCFAs), mainly butyrate, propionate, and acetate. These metabolites play a key role in maintaining intestinal barrier integrity and in the energy metabolism of colonocytes.
When microbial composition or function is altered, whether in diversity, relative proportions, or metabolic pathways, a state of dysbiosis occurs. This imbalance is frequently observed in various pathological conditions and has been associated with the development of diseases such as diabetes, certain cancers, atherosclerosis, asthma, inflammatory bowel diseases (IBD), and even depression.
IBD encompasses Crohn's disease (CD) and ulcerative colitis (UC). While CD is characterized by discontinuous lesions throughout the gastrointestinal tract, UC involves continuous and superficial inflammation of the colon. These pathologies affect 0.3-0.5% of the global population. Numerous studies have demonstrated significant differences in microbiota composition between IBD patients and healthy individuals, leading to impaired intestinal barrier function.
In parallel, a growing body of evidence suggests that the gut microbiota of physically active individuals differs from that of sedentary people.
More recently, our laboratory characterized the gut microbiota of 50 volunteers ranging from inactive individuals to elite athletes with high (elite football players) and very high (elite cyclists) exercise capacities. Our data revealed that exercise capacity influences gut microbial ecology and fecal SCFA levels, independently of diet. Interestingly, individuals with very high exercise capacity displayed reduced microbial diversity, density, and functional pathway abundance, raising questions about whether such microbial ecosystems are beneficial for host energy metabolism and exercise performance. Using FMT from human donors in our cohort to antibiotic-treated mice, we further demonstrated that donor microbiota, linked to exercise capacity, affects insulin sensitivity and muscle glycogen storage in recipient mice, highlighting the critical role of exercise-associated gut microbiota in shaping host metabolic responses.
In this context, this clinical study aims to characterize the bacterial metagenome of the gut microbiota across a continuum ranging from sedentary individuals to elite athletes with high or very high energy demands, and to determine whether specific gut microbiota composition and functional profiles are associated with different levels of exercise capacity. The ultimate goal of this project is to create a fecal microbiota biobank for future research on intestinal health.
The MICROPEPS clinical protocol is a prospective, single-center, comparative, and minimally interventional study. No drug, medical device, or product will be tested within this protocol. The study will be conducted at the Exermove platform (M2S Laboratory) to evaluate exercise capacity and the metagenomic signature of the gut microbiota in active, trained, and highly trained endurance men. Participants will attend three laboratory visits:
- Inclusion visit: anthropometric measurements, dietary and physical activity questionnaires. Participants will then receive a fecal collection kit to collect and send a stool sample within seven days.
- Second visit: incremental cycling test to determine VO₂max.
- Third visit: metabolic assessments under fasting conditions, at rest and during submaximal exercise.
Metabolic parameters measured during these tests (e.g., VO₂max, power output at aerobic and anaerobic thresholds, maximal carbohydrate and lipid oxidation) will be correlated with metagenomic shotgun data obtained from fecal samples.
Additionally, the study will establish a fecal microbiota biobank of donors stratified by exercise capacity. Using a mouse model of fecal microbiota transplantation combined with DSS-induced colitis, the final aim is to determine how donor exercise capacity and gut microbial ecosystems influence inflammatory responses and intestinal permeability
- Conditions
- Healthy
- Being tested
- Maximal incremental exercise test, Submaximal exercise test, Fecal sampling
- Keywords
- Physical activity, Gut microbiota, Intestinal health, exercise capacity, colitis
- Medical subject headings
- Motor Activity, Colitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Maximal incremental exercise testDiagnostic test
Participants will perform this test on a cycle ergometer. Gas exchange will be continuously measured throughout the test, and blood lactate will be sampled at regular intervals until maximal oxygen consumption is reached.
Submaximal exercise testDiagnostic test
A 25-min submaximal exercise test on ergocycle under fasting condition. Gas exchanges are measured during all the test and blood lactate will be sampled at regular intervals.
Fecal samplingBiological
Fecal samples will be collected in order to (1) conduct metagenomic and metabolomic analyses to characterize the gut microbiota composition and function, and (2) create a fecal biobank for future research involving fecal microbiota transplantation in mice.
| Study group | Role | What they receive |
|---|---|---|
| Low to moderate active subjects | V̇O₂max : 40-50 ml/min/kg Receives: Diagnostic Test: Maximal incremental exercise test; Diagnostic Test: Submaximal exercise test; Biological: Fecal sampling | |
| Trained subjects | V̇O₂max : 50-65 ml/min/kg Receives: Diagnostic Test: Maximal incremental exercise test; Diagnostic Test: Submaximal exercise test; Biological: Fecal sampling | |
| Highly trained subjects | V̇O₂max > 65 ml/min/kg Receives: Diagnostic Test: Maximal incremental exercise test; Diagnostic Test: Submaximal exercise test; Biological: Fecal sampling |
What is being measured
The primary outcome is the main question the study is designed to answer.
Gut microbiota composition (α-diversity)
The primary outcome measure will be α-diversity (i.e., Shannon index) assessed from fecal samples collected from each participant. This index will serve as the main criterion to detect gut microbiota remodeling associated with training status and key parameters of aerobic performance.
After transforming the continuous quantitative variables into discrete variables according to standardized performance scales, we will evaluate whether statistical differences exist in α-diversity between the defined groups using comparative statistical analyses (parametric or non-parametric depending on data distribution).
This approach aims to identify associations between gut microbial biodiversity, training status, and aerobic performance, with the broader goal of exploring microbial signatures potentially beneficial to intestinal health.
Measured: Week 1
Secondary outcomes (2)
β-diversity (i.e., differences between samples)
To determine whether the β-diversity (i.e., differences between samples) of the gut microbiota can discriminate between groups of participants classified according to key variables of aerobic performance (e.g., VO₂max, carbohydrate and lipid oxidation, ventilatory thresholds 1 and 2).
Measured: Week 1
Establish a fecal biobank
To establish a fecal biobank for future functional analyses using a murine model of intestinal inflammation.
Measured: Week 1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Dec 2025
- Study start17 Nov 2025
- Primary completion9 May 2026
- Study completion18 Jun 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (8)Papers the sponsor has linked to this study.
- Other trials for HealthyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 30 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Rennes 2
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Frédéric Derbré, University of Rennes 2
- Investigators
- Frédéric DERBRE, PhD, Principal investigator, Laboratory of Movement, Sport and health Sciences (M2S)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07276464
- Sponsor's protocol ID
- 2025-A01645-44
- Acronym
- MICROPEPS
- Status last verified
- Jun 2026
- First submitted
- 28 Nov 2025
- Last updated
- 23 Jun 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Martin D, Bonneau M, Orfila L, Horeau M, Hazon M, Demay R, Lecommandeur E, Boumpoutou R, Guillotel A, Guillemot P, Croyal M, Cressard P, Cressard C, Cuzol A, Monbet V, Derbre F. Atypical gut microbial ecosystem from athletes with very high exercise capacity improves insulin sensitivity and muscle glycogen store in mice. Cell Rep. 2025 Apr 22;44(4):115448. doi: 10.1016/j.celrep.2025.115448. Epub 2025 Mar 27.
PubMed 40154488Mohr AE, Jager R, Carpenter KC, Kerksick CM, Purpura M, Townsend JR, West NP, Black K, Gleeson M, Pyne DB, Wells SD, Arent SM, Kreider RB, Campbell BI, Bannock L, Scheiman J, Wissent CJ, Pane M, Kalman DS, Pugh JN, Ortega-Santos CP, Ter Haar JA, Arciero PJ, Antonio J. The athletic gut microbiota. J Int Soc Sports Nutr. 2020 May 12;17(1):24. doi: 10.1186/s12970-020-00353-w.
PubMed 32398103Barton W, Penney NC, Cronin O, Garcia-Perez I, Molloy MG, Holmes E, Shanahan F, Cotter PD, O'Sullivan O. The microbiome of professional athletes differs from that of more sedentary subjects in composition and particularly at the functional metabolic level. Gut. 2018 Apr;67(4):625-633. doi: 10.1136/gutjnl-2016-313627. Epub 2017 Mar 30.
PubMed 28360096Clarke SF, Murphy EF, O'Sullivan O, Lucey AJ, Humphreys M, Hogan A, Hayes P, O'Reilly M, Jeffery IB, Wood-Martin R, Kerins DM, Quigley E, Ross RP, O'Toole PW, Molloy MG, Falvey E, Shanahan F, Cotter PD. Exercise and associated dietary extremes impact on gut microbial diversity. Gut. 2014 Dec;63(12):1913-20. doi: 10.1136/gutjnl-2013-306541. Epub 2014 Jun 9.
PubMed 25021423Qiu P, Ishimoto T, Fu L, Zhang J, Zhang Z, Liu Y. The Gut Microbiota in Inflammatory Bowel Disease. Front Cell Infect Microbiol. 2022 Feb 22;12:733992. doi: 10.3389/fcimb.2022.733992. eCollection 2022.
PubMed 35273921Oligschlaeger Y, Yadati T, Houben T, Condello Olivan CM, Shiri-Sverdlov R. Inflammatory Bowel Disease: A Stressed "Gut/Feeling". Cells. 2019 Jun 30;8(7):659. doi: 10.3390/cells8070659.
PubMed 31262067Estaki M, Pither J, Baumeister P, Little JP, Gill SK, Ghosh S, Ahmadi-Vand Z, Marsden KR, Gibson DL. Cardiorespiratory fitness as a predictor of intestinal microbial diversity and distinct metagenomic functions. Microbiome. 2016 Aug 8;4(1):42. doi: 10.1186/s40168-016-0189-7.
PubMed 27502158Hou K, Wu ZX, Chen XY, Wang JQ, Zhang D, Xiao C, Zhu D, Koya JB, Wei L, Li J, Chen ZS. Microbiota in health and diseases. Signal Transduct Target Ther. 2022 Apr 23;7(1):135. doi: 10.1038/s41392-022-00974-4.
PubMed 35461318
Study at a glance
From the registry record, last updated by the sponsor on 23 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Characterization of the Gut Microbiota Metagenomic Signature According to Physical Fitness and Its Implications for Intestinal Health.
- ClinicalTrials.gov ID
- NCT07276464
- Acronym / sponsor ID
- MICROPEPS / 2025-A01645-44
- Conditions
- Healthy
- Keywords
- Physical activity, Gut microbiota, Intestinal health, exercise capacity, colitis
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 30 participants (actual)
- Lead sponsor
- University of Rennes 2University, hospital or other
- Study start
- 17 Nov 2025 (actual)
- Primary completion
- 9 May 2026 (actual)
- Study completion
- 18 Jun 2026 (actual)
- First posted
- 11 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The gut microbiota comprises all microorganisms inhabiting the digestive tract, evolving throughout life under the influence of various intrinsic and extrinsic factors. Under healthy conditions, the microbiota remains stable, resilient, and maintains a symbiotic relationship with its host. Conversely, dysbiosis refers to an alteration in microbial composition and function, which has been linked to diseases such as inflammatory bowel disease (IBD). IBD, including Crohn's disease and ulcerative colitis, is associated with a disrupted microbiota compared to healthy individuals, leading to impaired intestinal barrier integrity and activation of local inflammatory pathways.
Increasing evidence also suggests that the gut microbiota of athletes differs from that of physically inactive individuals, showing greater microbial diversity and higher concentrations of short-chain fatty acids (SCFAs). In this context, the present clinical study aims to characterize the bacterial metagenome of the gut microbiota across a continuum ranging from inactive individuals to elite athletes with high or very high energy demands. The ultimate goal of this project is to determine whether specific gut microbiota composition and functional profiles are associated with different levels of exercise capacity, and to create a fecal microbiota biobank for future research on intestinal health.
Detailed description
The gut microbiota includes all microorganisms-bacteria, viruses, and fungi-that inhabit the digestive tract. Colonization begins at birth and evolves throughout life under the influence of numerous factors such as diet, antibiotic use, sleep, stress, physical activity, exposure to environmental agents, as well as age, sex, and ethnic or migratory background.
This microbial ecosystem performs several essential functions for its host, including digestion and nutrient absorption, immune regulation, and protection against pathogens. Through the fermentation of complex carbohydrates, particularly dietary fibers indigestible by human enzymes, certain bacteria produce short-chain fatty acids (SCFAs), mainly butyrate, propionate, and acetate. These metabolites play a key role in maintaining intestinal barrier integrity and in the energy metabolism of colonocytes.
When microbial composition or function is altered, whether in diversity, relative proportions, or metabolic pathways, a state of dysbiosis occurs. This imbalance is frequently observed in various pathological conditions and has been associated with the development of diseases such as diabetes, certain cancers, atherosclerosis, asthma, inflammatory bowel diseases (IBD), and even depression.
IBD encompasses Crohn's disease (CD) and ulcerative colitis (UC). While CD is characterized by discontinuous lesions throughout the gastrointestinal tract, UC involves continuous and superficial inflammation of the colon. These pathologies affect 0.3-0.5% of the global population. Numerous studies have demonstrated significant differences in microbiota composition between IBD patients and healthy individuals, leading to impaired intestinal barrier function.
In parallel, a growing body of evidence suggests that the gut microbiota of physically active individuals differs from that of sedentary people.
More recently, our laboratory characterized the gut microbiota of 50 volunteers ranging from inactive individuals to elite athletes with high (elite football players) and very high (elite cyclists) exercise capacities. Our data revealed that exercise capacity influences gut microbial ecology and fecal SCFA levels, independently of diet. Interestingly, individuals with very high exercise capacity displayed reduced microbial diversity, density, and functional pathway abundance, raising questions about whether such microbial ecosystems are beneficial for host energy metabolism and exercise performance. Using FMT from human donors in our cohort to antibiotic-treated mice, we further demonstrated that donor microbiota, linked to exercise capacity, affects insulin sensitivity and muscle glycogen storage in recipient mice, highlighting the critical role of exercise-associated gut microbiota in shaping host metabolic responses.
In this context, this clinical study aims to characterize the bacterial metagenome of the gut microbiota across a continuum ranging from sedentary individuals to elite athletes with high or very high energy demands, and to determine whether specific gut microbiota composition and functional profiles are associated with different levels of exercise capacity. The ultimate goal of this project is to create a fecal microbiota biobank for future research on intestinal health.
The MICROPEPS clinical protocol is a prospective, single-center, comparative, and minimally interventional study. No drug, medical device, or product will be tested within this protocol. The study will be conducted at the Exermove platform (M2S Laboratory) to evaluate exercise capacity and the metagenomic signature of the gut microbiota in active, trained, and highly trained endurance men. Participants will attend three laboratory visits:
- Inclusion visit: anthropometric measurements, dietary and physical activity questionnaires. Participants will then receive a fecal collection kit to collect and send a stool sample within seven days.
- Second visit: incremental cycling test to determine VO₂max.
- Third visit: metabolic assessments under fasting conditions, at rest and during submaximal exercise.
Metabolic parameters measured during these tests (e.g., VO₂max, power output at aerobic and anaerobic thresholds, maximal carbohydrate and lipid oxidation) will be correlated with metagenomic shotgun data obtained from fecal samples.
Additionally, the study will establish a fecal microbiota biobank of donors stratified by exercise capacity. Using a mouse model of fecal microbiota transplantation combined with DSS-induced colitis, the final aim is to determine how donor exercise capacity and gut microbial ecosystems influence inflammatory responses and intestinal permeability
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Low to moderate active subjects | – | Diagnostic Test: Maximal incremental exercise test, Diagnostic Test: Submaximal exercise test, Biological: Fecal samplingV̇O₂max : 40-50 ml/min/kg |
| Trained subjects | – | Diagnostic Test: Maximal incremental exercise test, Diagnostic Test: Submaximal exercise test, Biological: Fecal samplingV̇O₂max : 50-65 ml/min/kg |
| Highly trained subjects | – | Diagnostic Test: Maximal incremental exercise test, Diagnostic Test: Submaximal exercise test, Biological: Fecal samplingV̇O₂max > 65 ml/min/kg |
Who may qualify
- Ages
- 18 to 30 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- Populations located in a continuum from inactive people to top-level athletes with high and very high exercise capacity.
Key inclusion criteria (11 listed)
- Male participant
- Aged between 18 and 30 years (inclusive)
- Body Mass Index (BMI) between 18 and 25 kg/m² (inclusive)
- No history of gastrointestinal disease, including inflammatory bowel disease
- Be a non-smoker.
Key exclusion criteria (6 listed)
- History of cardiovascular disease.
- Presence of a metabolic disorder (e.g., diabetes).
- Use of antibiotics, antifungal, or antiparasitic agents within the past 3 months, or planned use during participation in the study.
- Use of prebiotic and/or probiotic supplements within the 7 days preceding the study, providing ≥10⁸ CFU or organisms per day.
- Current use of medication for chronic pain management, including paracetamol, vasodilators, homeopathic treatments, or aspirin at doses >500 mg/day.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Maximal incremental exercise testParticipants will perform this test on a cycle ergometer. Gas exchange will be continuously measured throughout the test, and blood lactate will be sampled at regular intervals until maximal oxygen consumption is reached. | Diagnostic test | Highly trained subjects, Low to moderate active subjects, Trained subjects |
| Submaximal exercise testA 25-min submaximal exercise test on ergocycle under fasting condition. Gas exchanges are measured during all the test and blood lactate will be sampled at regular intervals. | Diagnostic test | Highly trained subjects, Low to moderate active subjects, Trained subjects |
| Fecal samplingFecal samples will be collected in order to (1) conduct metagenomic and metabolomic analyses to characterize the gut microbiota composition and function, and (2) create a fecal biobank for future research involving fecal microbiota transplantation in mice. | Biological | Highly trained subjects, Low to moderate active subjects, Trained subjects |
Primary outcome
Gut microbiota composition (α-diversity)
Time frame: Week 1
The primary outcome measure will be α-diversity (i.e., Shannon index) assessed from fecal samples collected from each participant. This index will serve as the main criterion to detect gut microbiota remodeling associated with training status and key parameters of aerobic performance. After transforming the continuous quantitative variables into discrete variables according to standardized performance scales, we will evaluate whether statistical differences exist in α-diversity between the defined groups using comparative statistical analyses (parametric or non-parametric depending on data distribution). This approach aims to identify associations between gut microbial biodiversity, training status, and aerobic performance, with the broader goal of exploring microbial signatures potentially beneficial to intestinal health.
2 secondary outcomes
β-diversity (i.e., differences between samples)
Time frame: Week 1
Establish a fecal biobank
Time frame: Week 1
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Jun 2026.
- Results publication: PubMed 40154488Martin D, Bonneau M, Orfila L, Horeau M, Hazon M, Demay R, Lecommandeur E, Boumpoutou R, Guillotel A, Guillemot P, Croyal M, Cressard P, Cressard C, Cuzol A, Monbet V, Derbre F. Atypical gut microbial ecosystem from athletes with very high exercise capacity improves insulin sensitivity and muscle glycogen store in mice. Cell Rep. 2025 Apr 22;44(4):115448. doi: 10.1016/j.celrep.2025.115448. Epub 2025 Mar 27.
- Results publication: PubMed 32398103Mohr AE, Jager R, Carpenter KC, Kerksick CM, Purpura M, Townsend JR, West NP, Black K, Gleeson M, Pyne DB, Wells SD, Arent SM, Kreider RB, Campbell BI, Bannock L, Scheiman J, Wissent CJ, Pane M, Kalman DS, Pugh JN, Ortega-Santos CP, Ter Haar JA, Arciero PJ, Antonio J. The athletic gut microbiota. J Int Soc Sports Nutr. 2020 May 12;17(1):24. doi: 10.1186/s12970-020-00353-w.
- Results publication: PubMed 28360096Barton W, Penney NC, Cronin O, Garcia-Perez I, Molloy MG, Holmes E, Shanahan F, Cotter PD, O'Sullivan O. The microbiome of professional athletes differs from that of more sedentary subjects in composition and particularly at the functional metabolic level. Gut. 2018 Apr;67(4):625-633. doi: 10.1136/gutjnl-2016-313627. Epub 2017 Mar 30.
- Results publication: PubMed 25021423Clarke SF, Murphy EF, O'Sullivan O, Lucey AJ, Humphreys M, Hogan A, Hayes P, O'Reilly M, Jeffery IB, Wood-Martin R, Kerins DM, Quigley E, Ross RP, O'Toole PW, Molloy MG, Falvey E, Shanahan F, Cotter PD. Exercise and associated dietary extremes impact on gut microbial diversity. Gut. 2014 Dec;63(12):1913-20. doi: 10.1136/gutjnl-2013-306541. Epub 2014 Jun 9.
- Results publication: PubMed 35273921Qiu P, Ishimoto T, Fu L, Zhang J, Zhang Z, Liu Y. The Gut Microbiota in Inflammatory Bowel Disease. Front Cell Infect Microbiol. 2022 Feb 22;12:733992. doi: 10.3389/fcimb.2022.733992. eCollection 2022.
- Results publication: PubMed 31262067Oligschlaeger Y, Yadati T, Houben T, Condello Olivan CM, Shiri-Sverdlov R. Inflammatory Bowel Disease: A Stressed "Gut/Feeling". Cells. 2019 Jun 30;8(7):659. doi: 10.3390/cells8070659.
- Results publication: PubMed 27502158Estaki M, Pither J, Baumeister P, Little JP, Gill SK, Ghosh S, Ahmadi-Vand Z, Marsden KR, Gibson DL. Cardiorespiratory fitness as a predictor of intestinal microbial diversity and distinct metagenomic functions. Microbiome. 2016 Aug 8;4(1):42. doi: 10.1186/s40168-016-0189-7.
- Results publication: PubMed 35461318Hou K, Wu ZX, Chen XY, Wang JQ, Zhang D, Xiao C, Zhu D, Koya JB, Wei L, Li J, Chen ZS. Microbiota in health and diseases. Signal Transduct Target Ther. 2022 Apr 23;7(1):135. doi: 10.1038/s41392-022-00974-4.
- Individual participant dataSharing planned: No
Related trials for Healthy
Recruiting
THE EFFECTS OF GAME-BASED EXERCISE PROGRAMS
Physical Activity, Body Image
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Frédéric DERBRE, PhD principal investigator
Laboratory of Movement, Sport and health Sciences (M2S)
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Healthy, run by University of Rennes 2 at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Gut microbiota composition (α-diversity) (time frame: Week 1). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07276464, which also lists 8 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jun 2026.